• Venkateswaramurthy N. Department of Pharmacy Practice, J.K.K Nattraja College of Pharmacy, Komarapalayam, Tamilnadu 638183, India
  • Krishnaveni K Department of Pharmacy Practice, J.K.K Nattraja College of Pharmacy, Komarapalayam, Tamilnadu 638183, India
  • Mercy Freeda R. Department of Pharmacy Practice, J.K.K Nattraja College of Pharmacy, Komarapalayam, Tamilnadu 638183, India
  • Sambath Kumar R. Department of Pharmaceutics, J.K.K Nattraja College of Pharmacy, Komarapalayam, Tamilnadu 638183, India


Objective: To assess the incidence and pattern of potential drug-drug interaction (pDDI) in hospitalized stroke patients.

Methods: A retrospective study was carried out in a medical record from a tertiary care teaching hospital for a 4 mo period from November 2015-February 2016. The total of 200 prescriptions was analyzed during the study period.

Results: A significant proportion of patients with pDDIs were males (61.5%) followed by females (38.5%). Among the 200 prescriptions, 179(89.5%) were confirmed with minimum one potential drug-drug interaction. Moreover, patients prescribed with more than 5 drugs developed a higher number of interactions. Based on severity scale, there were 125 major, 375 moderate and 128 minor interactions were observed. The pharmacodynamic interactions were 286 while the pharmacokinetic were 342.

Conclusion: The study highlighted the pDDIs which were high in stroke patients greater than 40 y. pDDIs in prescriptions contained multi-drug therapy is a major concern as such interaction may lead to increased risk of hospitalization and higher health care cost. The majority of interactions were pharmacokinetic in nature, having moderate severity. In this study pDDIs mainly occurred between antihypertensive, anticoagulants and antiplatelet.

Keywords: Stroke, Potential drug-drug interactions, Prescriptions, Pharmacokinetic and pharmacodynamic


Download data is not yet available.


1. Morales-Olivas FJ, Estan L. Antihypertensive drug-drug interactions. Med Clin 2005;124:782–9.
2. Gupta R. Burden of coronary heart disease in India. Indian Heart J 2005;57:632–8.
3. Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertension 2004;18:73–8.
4. World Health Organisation. Preventing chronic diseases: a vital investment: WHO global report. Geneva, Switzerland; 2005.
5. Dalal PM, Malik S, Bhattacharjee M, Trivedi ND, Vairale J, Bhat P, et al. Population-bases stroke survey in Mumbai, India: Incidence and 28-day case fatality. Neuroepidemiology 2008;31:254-61.
6. Costa AJ. Potential drug interactions in an ambulatory geriatric population. Fam Pract 1991;8:234–6.
7. Hansten PD. Drug interaction management. Pharm World Sci 2003;25:94–7.
8. Mahmood M, Malone DC, Skrepnek GH, Abarka J, Armstrong EP, Murphy JE, et al. Potential drug-drug interactions within veterans affairs medical centers. Am J Health Syst Pharm 2007;64:1500–5.
9. Merlo J, Liedholm H, Lindblad U, Bjorck-Linne A, Falt J, Lindberg G, et al. Prescriptions with potential drug interaction dispensed at Swedish pharmacies in January 1999: cross sectional study. Br Med J 2001;323:427–8.
10. Sameer D, Milind P. Assessment of a drug interaction of antidepressants with other prescribed drugs. Asian J Pharm clin Res 2011;4 Suppl 1:102-4.
11. Micromedex® solutions. Truven Health analytics (internet database). Greenwood village, colo: Thomson Reuters (healthcare) Inc; 1995.
12. Jeyaraj DP, Paulin Sudhan. Stroke epidemiology and stroke care services in India. J Stroke 2013;15:128-34.
13. Eric R, Bates DM, Wei CL. Drug–drug interactions involving antiplatelet agents. Eur Heart J 2003;24:1707–9.
14. Vijayakumar S, Ravi kanth S, Ayesha S, Dheeraj Kumar G. Drug-drug interaction is occurring during hospital stay among stroke patients. Afr J Pharm Pharmacol 2012;6:2670-4.
15. Sridharan, Unnikrishnan JP, Sukumaran S, Sylaja PN, Nayak SD, Sarma PS, et al. Incidence, types, risk factors and outcome of stroke in a developing country: the trivandrum stroke registry. Stroke 2009;40:1212-8.
16. Celin AT, Seuma J, Ramesh A. Assessment of drug-related problems in stroke patients admitted to a South Indian tertiary care teaching hospital. Indian J Pharm Pract 2012;5:28-33.
17. Mateti UV, Rajakannan T, Nekkanti H, Rajesh V, Mallaysamy SR, Ramachandran P. Drug–drug interactions in hospitalized cardiac patients. J Young Pharm 2011;3:329–33.
18. Sivva D, Mateti UV, Neerati VM, Thiruthopu NS, Martha S. Assessment of drug-drug interactions in hypertensive patients at a super-speciality hospital. Avicenna J Med 2015;5:29-35.
19. UK national patient safety agency. Risk assessment of anticoagulants therapy. Available from: http://www. pdf. [Last accessed on 30 Sep 2016]
20. Gouya G, Reichardt B, Ohrenberger G, Wolzt M. Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy. Eur J Epidemiol 2007;22:145-9.
436 Views | 2423 Downloads
How to Cite
N., V., K. K, M. F. R., and S. K. R. “ASSESSMENT OF POTENTIAL DRUG–DRUG INTERACTION IN STROKE PATIENTS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 8, no. 12, Dec. 2016, pp. 221-4, doi:10.22159/ijpps.2016v8i12.13878.
Original Article(s)